Despite the impressive advances in suppressing the pathological activity of RA-FLSs via PI3K/AKT/mTOR inhibitors, the problem of verifying the long-term stability of phenotypic and molecular alterations after cessation of therapy remains unresolved. The gene discussed is AKT1; the disease is rheumatoid arthritis.